Table 2.

Cyclin D1, CDK4 and p16 expression in breast cancer in relation to clinicopathological variables

	Cyclin D1 - n (%)	Cyclin D1 + n (%)	P-value	Cdk4 - n (%)	Cdk4 + n (%)	P-value	P16 - n (%)	p16 + n (%)	P-value
Tumour
T1	21 (52.5)	41 (73.2)		14 (56.0)	39 (65.0)		27 (64.3)	32 (62.7)
T2	13 (32.5)	12 (21.4)		10 (40.0)	14 (23.4)		10 (23.8)	15 (29.4)
T3	3 (7.5)	3 (5.4)		1 (4.0)	5 (8.3)		2 (4.8)	4 (7.8)
T4	3 (7.5)	0 (0.0)		0 (0.0)	2 (3.3)		3 (7.1)	0 (0.0)
			0.066			0.431			0.273
Nodus
Negative	20 (51.3)	34 (61.8)		15 (65.2)	34 (56.7)		26 (61.9)	29 (59.2)
Positive	19 (48.7)	21 (38.2)		8 (34.8)	26 (43.3)		16 (38.1)	20 (40.8)
			0.309			0.478			0.791
Grade
I	9 (22.5)	20 (35.7)		11 (44.0)	14 (23.3)		11 (26.2)	17 (33.3)
II	10 (25.0)	23 (41.1)		6 (24.0)	22 (36.7)		14 (33.3)	16 (31.4)
III	21 (52.5)	13 (23.2)		8 (32.0)	24 (40.0)		17 (42.5)	18(35.3)
			0.013*			0.156			0.747
Estrogen receptor (ER)
Negative	18 (45.0)	3 (5.4)		6 (24.0)	14 (23.3)		10 (23.8)	12 (23.5)
Positive	22 (55.0)	53 (96.6)		19 (76.0)	46 (76.7)		32 (76.2)	39 (76,5)
			0.000***			0.947			0.975
Progesterone receptor (PR)
Negative	18 (45.0)	13 (23.3)		8 (32.0)	22 (36.7)		15 (35.7)	18 (35.3)
Positive	22 (55.00)	43 (76.8)		17 (68.0)	38 (63.3)		27 (64.3)	33 (64.7)
			0.024*			0.682			0.966
HER2
Negative	30 (75.0)	48 (85.7)		21 (84.0)	48 (80.0)		28 (66.7)	47 (92.2)
Positive	10 (25.0)	8 (14.3)		4 (16.0)	12 (20.0)		14 (33.3)	4 (7.8)
			0.185			0.769			0.002**
Ki67
Negative	8 (20.0)	12 (21.4)		6 (24.0)	9 (15.0)		8 (19.0)	10 (19.6)
+	10 (25.0)	24 (42.9)		11 (44.0)	21 (35.0)		15 (35.7)	18 (35.3)
++	7 (17.5)	13 (23.2)		2 (8.0)	16 (26.7)		10 (23.8)	9 (17.6)
+++	15 (37.5)	7 (12.5)		6 (24.0)	14 (23.3)		9 (21.4)	14 (27.5)
			0.031*			0.251			0.856

* P < 0.05, ** P < 0.01, *** P < 0.001.